Yesterday, Feb. 18, 2016, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $20.83 to $7,091,400.00.

Highlighted Stocks Traded by Insiders:

Shutterfly (SFLY) - FREE Research Report

Housenbold Jeffrey T, who is President & Ceo at Shutterfly, sold 51,120 shares at $39.35 on Feb. 18, 2016. Following this transaction, the President & Ceo owned 268,957 shares meaning that the stake was reduced by 15.97% with the 51,120-share transaction.

Black Dwayne A, who is SVP, Operations at Shutterfly, sold 5,312 shares at $39.35 on Feb. 18, 2016. Following this transaction, the SVP, Operations owned 127,657 shares meaning that the stake was reduced by 3.99% with the 5,312-share transaction.

McCormick Dan, who is SVP & Chief Operating Officer at Shutterfly, sold 14,808 shares at $39.35 on Feb. 18, 2016. Following this transaction, the SVP & Chief Operating Officer owned 63,567 shares meaning that the stake was reduced by 18.89% with the 14,808-share transaction.

Boris John, who is SVP, Chief Marketing Officer at Shutterfly, sold 3,916 shares at $39.35 on Feb. 18, 2016. Following this transaction, the SVP, Chief Marketing Officer owned 34,688 shares meaning that the stake was reduced by 10.14% with the 3,916-share transaction.

The shares most recently traded at $40.06, up $0.71, or 1.76% since the insider transaction. Historical insider transactions for Shutterfly go as follows:

  • 4-Week # shares bought: 15,000
  • 4-Week # shares sold: 25,447
  • 12-Week # shares bought: 15,000
  • 12-Week # shares sold: 25,447
  • 24-Week # shares bought: 15,000
  • 24-Week # shares sold: 32,667

The average volume for Shutterfly has been 451,400 shares per day over the past 30 days. Shutterfly has a market cap of $1.4 billion and is part of the services sector and diversified services industry. Shares are down 13.4% year-to-date as of the close of trading on Thursday.

Shutterfly, Inc. manufactures and retails in digital personalized products and services in the United States. It offers a range of personalized photo-based products and services for consumers to upload, edit, enhance, organize, find, share, create, print, and preserve their memories. Currently, there are 5 analysts who rate Shutterfly a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SFLY - FREE

TheStreet Quant Ratings

rates Shutterfly as a

hold

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and revenue growth. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Shutterfly Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Validus Holdings (VR) - FREE Research Report

Grayson Matthew J., who is Director at Validus Holdings, sold 5,250 shares at $44.85 on Feb. 18, 2016. Following this transaction, the Director owned 122,810 shares meaning that the stake was reduced by 4.1% with the 5,250-share transaction.

The shares most recently traded at $45.34, up $0.49, or 1.08% since the insider transaction. Historical insider transactions for Validus Holdings go as follows:

  • 4-Week # shares sold: 25,631
  • 12-Week # shares bought: 48
  • 12-Week # shares sold: 111,055
  • 24-Week # shares bought: 48

TheStreet Recommends

  • 24-Week # shares sold: 118,378

The average volume for Validus Holdings has been 531,200 shares per day over the past 30 days. Validus Holdings has a market cap of $3.7 billion and is part of the financial sector and insurance industry. Shares are down 2.16% year-to-date as of the close of trading on Thursday.

Validus Holdings, Ltd. provides reinsurance coverage, insurance coverage, and insurance linked securities management services worldwide. It operates through four segments: Validus Re, AlphaCat, Talbot, and Western World. The stock currently has a dividend yield of 3.13%. The company has a P/E ratio of 9.5. Currently, there is 1 analyst who rates Validus Holdings a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VR - FREE

TheStreet Quant Ratings

rates Validus Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Validus Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Thiel Carsten, who is EVP, Chief Commercial Officer at Alexion Pharmaceuticals, sold 187 shares at $143.49 on Feb. 18, 2016. Following this transaction, the EVP, Chief Commercial Officer owned 36,633 shares meaning that the stake was reduced by 0.51% with the 187-share transaction.

The shares most recently traded at $145.10, up $1.61, or 1.11% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 3,067
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 75,855
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 84,413

The average volume for Alexion Pharmaceuticals has been 1.7 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $33.5 billion and is part of the health care sector and drugs industry. Shares are down 24.95% year-to-date as of the close of trading on Thursday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 221.8. Currently, there are 15 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings

rates Alexion Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full

Alexion Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.